Cardinal Health (CAH) Falls More Steeply Than Broader Market: What Investors Need to Know

Cardinal Health (CAH) recently experienced a 3.64% daily decline, underperforming the broader market, yet has appreciated 3.58% over the past month. The company faces high expectations, with Zacks Consensus Estimates projecting an 18.09% year-over-year increase in quarterly EPS to $2.22 and a 12.96% rise in revenue to $59.05 billion, coupled with strong annual growth forecasts. Despite a marginal 0.14% decrease in 30-day EPS estimates, CAH maintains a Zacks Rank #3 (Hold) and trades at a Forward P/E of 16.42, a premium to its industry's 14.68 average, though its PEG ratio of 1.31 is below the industry average of 1.65.

Analysis

Cardinal Health (CAH) presents a mixed technical and fundamental picture. The stock recently underperformed the broader market with a significant single-day decline of 3.64%, closing at $148.96. However, this short-term weakness is contrasted by its one-month performance, where it appreciated 3.58%, outpacing both the S&P 500's 2.74% gain and the Medical sector's 0.7% loss. Looking ahead, consensus estimates for its upcoming earnings report on October 30, 2025, are robust, projecting an 18.09% year-over-year increase in EPS to $2.22 and a 12.96% rise in revenue to $59.05 billion. This positive outlook is tempered by a slight 0.14% decrease in the Zacks Consensus EPS estimate over the past 30 days, contributing to its current Zacks Rank #3 (Hold) status. From a valuation perspective, CAH trades at a Forward P/E of 16.42, a premium to its industry average of 14.68. This premium may be partially justified by its PEG ratio of 1.31, which is more attractive than the industry average of 1.65, suggesting its growth rate is not fully priced in relative to peers. A notable headwind is its industry's poor standing, with the Medical - Dental Supplies group ranking in the bottom 32% of over 250 industries, a factor that historically correlates with underperformance.

Key Decisions for Investors

• Investors should closely monitor the upcoming October 30th earnings report, as a failure to meet the high consensus growth expectations for EPS (+18.09%) and revenue (+12.96%) could trigger significant downside given the recent price volatility.
• While the company's strong growth projections are compelling, the stock's premium Forward P/E of 16.42 and the recent downward analyst estimate revision warrant a cautious stance, consistent with its 'Hold' rating.
• Consider the divergence between CAH's strong one-month performance and its weak industry rank; continued outperformance depends on the company's ability to execute on its growth strategy, overcoming the headwinds affecting the broader Medical - Dental Supplies sector.